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Abstract 
Aims: Myocardial fibrosis (MF) is a deleterious consequence of aortic valve stenosis (AVS). Global longitudinal strain 
(GLS) is a novel left ventricular (LV) functional parameter potentially useful to non-invasively estimate MF. MicroRNAs 
(miRNAs) are non-coding small ribonucleic acids (RNA) modulating genes function, mainly through RNA degrada-
tion. miRNA-21 is a biomarker associated with MF in pressure overload. The aim of the present study was to find an 
integrated algorithm for detection of MF using a combined approach with both bio- and functional markers.
Methods: Thirty-six patients (75.2 ± 8 y.o.; 63 % Female) with severe AVS and preserved LV ejection fraction (EF), 
candidate to surgical aortic valve replacement (sAVR) were enrolled. Clinical, bio-humoral evaluation (including 
plasmatic miRNA-21 collected using specific tubes, PAXgene, for stabilization of peripheral RNA) and a complete 
echocardiographic study, including GLS and septal strain, were performed before sAVR. Twenty-eight of those 
patients underwent sAVR and, in 23 of them, an inter-ventricular septum biopsy was performed. Tissues were fixed in 
formalin and embedded in paraffin. Sections were stained with Hematoxylin and Eosin for histological evaluation and 
with histochemical Masson trichrome for collagen fibers. The different components were calculated and expressed 
as micrometers2. To evaluate tissue miRNA components, sections 2-μm thick were cut using a microtome blade for 
each slide. Regression analysis was performed to test association between dependent variable and various predictors 
included in the model.
Results: Despite a preserved EF (66 ± 11 %), patients presented altered myocardial deformation parameters (GLS 
−14,02 ± 3.8 %; septal longitudinal strain, SSL −9.63 ± 2.9 %; septal longitudinal strain rate, SL-Sr −0.58 ± 0.17 1/s; 
Septal Longitudinal early-diastolic strain rate, SL-SrE 0.62 ± 0.32 1/s). The extent of MF showed an inverse association 
with both GLS and septal longitudinal deformation indices (GLS: R2 = 0.30; p = 0.02; SSL: R2 = 0.36; p = 0.01; SL-Sr: 
R2 = 0.39; p < 0.001; SL-SrE: R2 = 0.35; p = 0.001). miRNA-21 was mainly expressed in fibrous tissue (p < 0.0001). A 
significant association between MF and plasmatic miRNA-21, alone and weighted for measures of structural (LVMi 
R2 = 0.50; p = 0.0005) and functional (SSL R2 = 0.35; p = 0.006) remodeling, was found.
Conclusions: In AVS, MF is associated with alterations of regional and global strain. Plasmatic miRNA-21 is directly 
related to MF and associated with LV structural and functional impairment.
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Background
Aortic valve stenosis (AVS) is the most common valvular 
heart disease in Western Countries [1, 2]. In particular, 
AVS is a slowly progressive disease, associated with sig-
nificant Left Ventricular (LV) pressure overload, which 
induces left ventricular hypertrophy (LVH) and second-
ary myocardial fibrosis (MF). MF is an early morphologic 
alteration in patients with AVS and a major determinant 
of LV functional impairment, ultimately leading to the 
development of heart failure.
Accordingly, robust and repeatable measures of MF 
that may be applied in the clinical field are eagerly 
awaited.
Nevertheless, the evaluation of patients with AVS is 
generally limited to the assessment of flow-dependent 
parameters (velocity; gradients) that reflect only the “val-
vular side” of the pathology, disregarding LV components 
of disease [3–5].
Beside the endo-myocardial biopsy (gold standard), 
not ethically feasible in a clinical setting, a series of bio-
markers and cardiac imaging techniques have been lately 
proposed to combine tissue parameters with functional 
evaluation. In this respect, the evaluation of LV deforma-
tion by Speckle Tracking Echocardiography (2D-STE) has 
been shown to allow a better assessment of cardiac con-
tractile function than traditional parameters [i.e. Ejection 
Fraction (EF)], giving the chance to assess the presence of 
subtle alterations of LV systolic performance. In particu-
lar, regional and global longitudinal strain (GLS), showed 
a better and earlier diagnostic power over EF, becoming 
reference indicators for the precocious assessment of sub-
clinical LV functional impairment [6–12]. More recently, 
measures obtained through 2D-STE showed to correlate 
with the presence and extent of MF at cardiac magnetic 
resonance, as assessed through T1-mapping and late gado-
linium enhancement as quantification techniques [13, 14].
MicroRNAs (miRNAs) are non-coding small ribonu-
cleic acids (RNAs) that modulate the expression of tar-
get genes inducing mRNA degradation. The expression 
of miRNAs is associated with multiple pathological pro-
cesses that affect also the cardiovascular system [15, 16].
A regulatory role for miRNA-21 has been evidenced 
in LV myocardial remodeling induced by hemodynamic 
stress [17, 18].
Recent reports indicate that the presence of circulating 
miRNAs may reflect specific cardiovascular pathologies 
and could be a useful biomarker for different cardiovas-
cular diseases.
Accordingly, the evaluation of both miRNA (as a bio-
marker) and GLS (as a functional marker), might allow 
an integrated assessment of the pathophysiological rela-
tionship between MF and adverse LV remodeling.
With these considerations in mind, we aimed at 
assessing:
a. the presence of MF (detected by endo-myocardial 
biopsy) both with gold standard histologic method 
and with an advanced laser micro-dissection meth-
odology (tissue miRNA-21), in patients with severe 
AVS;
b. the presence of a direct association between plas-
matic and tissue pool of miRNA-21;
c. the relationship between 2D-STE parameters, MF 
(endo-myocardial biopsy) and plasmatic/tissue 
miRNA-21 expression levels, in order to develop a 
non-invasive detection of myocardial fibrotic burden.
Methods
Study population
Thirty-six consecutive patients with severe sympto-
matic AVS (Peak Trans-valvular Velocity > 4 m/s; Mean 
Gradient  >  40  mmHg; Aortic Valve Area-AVA  <  1  cm2; 
AVAi  <  0.6  cm2/m2) and preserved EF, were prospec-
tively evaluated in University of Pisa Hospital (A.O.U.P) 
for sAVR. Patients underwent laboratory analysis (for 
36 patients brain natriuretic peptide, BNP pg/mL; high-
sensitive assays troponin T, hs-TnT, ng/L; plasmatic 
miRNA-21 assay for 30 patients), and trans-thoracic 
echocardiography (M-Mode, 2D, Doppler, Tissue Dop-
pler Imaging-TDI, 2D-STE). Twenty-eight patients were 
finally submitted to sAVR (three patients refused sur-
gery; five patients decision for percutaneous procedures), 
23 of whom (in 5 patients under-sampling/biopsy not 
performed) underwent intra-operatory basal inter-ven-
tricular septum biopsy to evaluate MF (23 patients) and 
tissutal levels of expression of miRNA-21 (20 patients). 
All patients signed an informed consent, approved by 
local ethical committee, conform to the ethical guidelines 
of the 1975 Declaration of Helsinki. We excluded patients 
with at least one of the following: age  <  18 y.o., signifi-
cant major comorbidities (i.e.cancer; dialysis; cachexia), 
inability to sign consent, pregnancy, poor acoustic win-
dow, ischemic heart disease (including epicardial coro-
nary artery disease > 50 %), associated valvular disease of 
moderate-severe degree, non-degenerative AVS, disky-
netic septum (i.e. stimulator; Left Bundle Branch Block).
Keywords: Aortic valve, Aortic stenosis, Aortic valve replacement, Tissue characterization, Tissue and strain Doppler 
echocardiography, Myocardial strain
Page 3 of 11Fabiani et al. J Transl Med  (2016) 14:248 
Conventional echocardiography
Transthoracic exams were performed with a dedicated 
machine (Vivid-7, General Electric Milwaukee, WI-
USA). Patients were imaged in the left lateral decubitus 
position and data were acquired with a 4  MHz (M4S) 
transducer at a depth of 16 cm in the parasternal (long- 
and short-axis views) and apical views (two- and four-
chamber and apical long-axis views). All parameters were 
derived according to current indications, and considered 
in relation to their established reference ranges [19, 20].
LV dimensions were calculated from the standard 
M-mode/2D images at the parasternal long-axis views 
and included LV diameters and end-diastolic thickness 
of the interventricular septum and posterior wall. Left 
ventricular mass was calculated and corrected by the 
body surface area to derive mass index (LVMi). The LV 
end-diastolic and end-systolic volumes were measured 
from the apical two- and four-chamber views, and EF was 
calculated using the Simpson’s rule. LV diastolic func-
tion was evaluated using early (E wave) and late (A wave) 
trans-mitral velocities, the E/A ratio, and the E wave 
deceleration time obtained from the spectral pulsed-wave 
Doppler recordings. In addition, TDI was performed, 
adjusting gain and frame rate to get an appropriate tis-
sue characterization. The aortic valve area (AVA; indexed, 
AVAi) was calculated by the continuity equation, and the 
maximum pressure gradient across the restrictive orifice 
was estimated by the modified Bernoulli equation. Mean 
trans-aortic pressure gradient was calculated averaging 
the instantaneous gradients over the ejection period on 
the continuous-wave Doppler recordings. As a meas-
urement of global left ventricular afterload, the valvulo-
arterial impedance (ZVA) was calculated. Finally, color 
Doppler echocardiography was performed after optimiz-
ing gain and Nyquist limit in order to evaluate the pres-
ence of regurgitant valve disease. The severity of valvular 
regurgitation was determined on a qualitative scale (mild, 
moderate, and severe), according to the current guide-
lines [19, 20].
Speckle tracking echocardiography
Assessment of LV GLS was performed using 2D-STE 
(frame rate 45–90  frame/s, fps). We limited the analy-
sis to the global longitudinal component of strain (peak 
value-mid myocardium). Quantifications were performed 
using the available software (EchoPAC 10, General Elec-
tric), as described previously [21–23]. For this purpose, 
standard 2D grey-scale images of the LV were acquired 
at conventional apical two- and four-chamber and api-
cal long-axis views. 2D-STE enables angle-independent 
myocardial deformation analysis by tracking frame-to-
frame natural acoustic markers, or speckles, that appear 
equally distributed within the myocardial wall. Applying 
the strain Lagrangian formula, the percentage change in 
myocardial length relative to the initial length derives 
myocardial strain (expressed in percentage). The tempo-
ral derivation of myocardial strain results in strain rate 
and is a measure of the rate of deformation. The longitu-
dinal deformation relates to motion from mitral annulus 
to the apex in the apical views and results in shortening 
(negative strain) and lengthening (positive strain). Using 
the dedicated application, the endocardial contour was 
manually traced at an end-systolic frame. The software 
then automatically traced a concentric region of interest 
(ROI), including the entire myocardial wall. The myo-
cardial tracking was verified, and the ROI width was 
adjusted to optimize the tracking, if needed. Next, seg-
mental strain analysis was performed dividing each LV 
image into six segments. Peak systolic parameters were 
calculated averaging the peak systolic values of the eight-
een segments, derived from the six segments of the three 
apical views (two- and four-chamber and apical long-
axis views). For dedicated septal analysis, a focused ROI 
(80–95/fps) was traced specifically for inter-ventricular 
septum. We assessed, septal longitudinal systolic strain 
(SSL), systolic (SL-Sr) and early-diastolic (SL-SrE) strain 
rates. We then averaged measure from anterior and infe-
rior septum. Intra and inter-observer variability analysis 
for 2D-STE was evaluated by intra/inter-class correlation 
coefficient (ICC). Ten randomly selected patients were 
evaluated three-times by the same operator (same 
beats; consecutive days). The same measurements were 
repeated in the same day by a second clinician, blinded to 
previous results. All ICC resulted >0.80 (p < 0.05), show-
ing good agreement.
Invasive measurements
In 22 patients, in addition to coronary angiography, 
standard left heart catheterization was performed before 
sAVR. Peak-to-peak gradient, invasive end-diastolic pres-
sure (EDPi; fluid-filled catheter) and semi-quantitative 
aortic regurgitation were evaluated.
Operating myocardial biopsy
In 23 patients undergoing sAVR, concomitant intra-
operatory basal left-side inter-ventricular septum biopsy 
was performed to assess MF, as previously described 
[24–26]. Briefly, tissues (30–80  mg) were fixed in 10  % 
formalin and embedded in paraffin. One Section (2 µm) 
was stained with Hematoxylin and Eosin for histological 
evaluation and one Section (5  µm) with histochemical 
Masson trichrome stain for collagen fibers. The different 
components of the myocardial biopsy were calculated by 
computer analysis (PALM MicroBeam, Carl Zeiss), and 
expressed as micrometers squared. In particular, the fol-
lowing parameters were analyzed:
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  • the overall myocardial area occupied by the myocytes 
and connective tissue (fibrotic area);
  • myocyte area
  • connective area
  • connective/overall myocardial area (ratio % as MF 
grading)
All measurements were made by two expert patholo-
gists without knowledge of the clinical data (intra-class 
and inter-observer correlation coefficients on 5 random 
samples of 0.9 and 0.94, respectively).
Origin of myocardial miRNA‑21
Immunohistochemistry
4-micron sections were dewaxed in xylene and rehy-
drated through graded alcohols to water. Antigen 
retrieval was performed microwaving sections for 9 min 
in citrate/EDTA buffer (pH 7.8). Not specific peroxidase 
activity was blocked with 3  % hydrogen peroxidase for 
15  min, and non-specific binding prevented by incuba-
tion with normal goat serum for 10  min. Afterwards, 
incubation with anti-vimentin mouse monoclonal anti-
body (clone VI10, Abcam, diluition 1:200) and anti-
CD45/LCA rabbit monoclonal antibody (clone EP68, Cell 
Marque, diluition 1:100) was performed for 1 h at room 
temperature. A biotin conjugated goat derived second-
ary antibody was applied followed by the Vectastain Elite 
ABC kit (Vector Laboratories). Slide were incubated with 
diaminobenzidine tetrahydrochloride (DAB) and coun-
terstained with hematoxylin.
miRNA‑21: plasmatic and tissue study
Blood samples
Peripheral blood samples were collected using specific 
tubes (PAXgene Blood RNA Tube) included in the com-
mercial systems for collection and immediate stabiliza-
tion of peripheral blood RNA (PreAnalytiX).
Tissue samples
For 20 biopsy specimens laser microdissection (LSMD) 
was performed. Sections  2-μm thick were cut from 
each case using a new microtome blade for each slide. 
The PALM MicroBeam laser micro-dissector from Carl 
Zeiss was used to select and collect cardiomyocytes and 
fibrotic cells to be studied separately.
RNA isolation
Blood RNA was purified using the commercial kit PAX-
gene Blood RNA Kit (PreAnalytiX). The quantity of 
extracted RNA was estimated with Qubit 2.0 Fluorom-
eter (Life Technologies) by using 2ul of undiluted RNA 
solution. Yield ranged from 50 to 500  ng/ul of RNA. 
Microdissected samples were incubated at 55  °C over-
night upside-down with 50 μl of lysis buffer and 10 μl of 
proteinase K. The day after the samples were loaded in 
Maxwell 16 Instrument (Promega) to extract RNA.
Reverse transcription and analysis of miRNA profiles
MicroRNAs were reverse transcribed from 6  µl of total 
extracted RNA sample using the miScript II RT Kit 
(QIAGEN). cDNA from micro dissected samples was 
pre-amplified prior to real-time PCR analysis of miRNA. 
miRNA expression analysis were performed in triplicate 
using 1  µl of diluted cDNA as a template for real-time 
PCR with the miScript SYBR Green PCR Kit (QIAGEN) 
and the miScript Primer Assays (SNORD61—assay code 
MS00033705, miRNA-21—assay code MS00009079 
(QIAGEN)) according to manufacturer’s instructions 
on the CFX96 Real Time system c1000 thermal cycler 
(BIORAD).
Data analysis
Data analysis was performed using the Bio-Rad CFX 
Manager Software v3.1 and Microsoft Excel. miRNA 21 
expression was calculated using SNORD61 expression 
level as reference and the relative normalized expression 
∆∆Cq formula.
Statistical analysis
The data sets were assessed for normality with the 
Kolmogorov–Smirnov test. Continuous variables are 
described as mean ± standard deviation (SD). Otherwise 
as median (with minimum/maximum). Categorical data 
are reported as percentage. Plasmatic and tissue miRNA-
21 levels of expression where measurable were treated 
as continuous variables. Continuous variables were 
compared using the Mann–Whitney U test when non-
Gaussian. Univariate linear regression analysis was per-
formed to test association between dependent variable 
and various potential predictors included in the model. 
We assessed also the association between Myocardial 
Fibrosis (Y) and Plasmatic miRNA-21 (X) weighted for 
left ventricular mass indexed for BSA and septal longi-
tudinal strain, respectively. The threshold for statistical 
significance was p < 0.05. In order to preserve the statis-
tical meaning of regression analysis (direct/inverse cor-
relation/association), in the text we considered global 
longitudinal strain/systolic strain rate in absolute value. 
Using a c-statistic approach we derived the miRNA-21 
value with the best combination of sensitivity and speci-
ficity for discrimination of patients with a significant 
amount of MF (more than 10 % of the specimen).
The following statistic package was used: Medcalc 12.7 
(Medcalc Software 2013, Belgium).
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Results
The characteristics of the population regarding clinical, 
laboratory and echocardiographic parameters are shown 
in Tables 1, 2 and 3.  
All patients (Tables  2 and 3) showed a significantly 
elevated left ventricular mass indexed (LVMi) for body 
surface area (BSA), with evidence of concentric LV 
hypertrophy. A variable degree of diastolic impair-
ment was observed, with increased EDPi and left atrial 
dimensions. LVMi didn’t show a significant association 
with indices of AVS severity (AVAi; Max/mean gradi-
ents; peak-to-peak gradient; Velocity Ratio; ZVA). Even if 
conventional indices of global systolic function were pre-
served (EF, Fractional shortening), more sensitive param-
eters of longitudinal function (e.g. Mitral annular plane 
systolic excursion, MAPSE; TDI; Table  2) were reduced 
when compared to normal ranges.
Table 1 Population characteristics
ACE angiotensin converting enzyme, AT-II angiotensin 2 receptor, BNP brain 
natriuretic peptide, BSA body surface area, CHD coronary heart disease, COPD 
chronic obstructive pulmonary disease, DAP diastolic arterial pressure, GFR 
glomerular filtration rate, HR heart rate, SAP systolic arterial pressure
Mean SD
General characteristics
Age (year) 75.2 8.06
BSA (m2) 1.8 0.17
Log EUROSCORE (%) 5.9 4.17
EUROSCORE II (%) 2.2 1.13
SAP (mmHg) 139.1 19.00
DAP (mmHg) 71.3 10.03
HR (bpm) 73.5 11.92
n %
Clinical characteristics
Female sex 23 63
CHD (</=50 % epicardial coronary) 12 33
COPD 8 22
Anemia 14 38
Chronic kidney dis. 22 61
Diabetes Mell. 8 22
Arterial hypertension 31 86
Dyslipidemia 21 58
n %
Drugs (admission)
ACE-inhibitors 15 41
AT-II-inhibitors 10 27
Anti-aldosteronic 2 5
Diuretics 14 38
Calcium-antagonist 6 10
Laboratory data Mean/Median* SD/Min–Max**
BNP (pg/mL) 250.9 220.4
GFR (mL/min/1.73 m2) 70.8 28.4
hsTnT (ng/L) 30.4 26.8
miRNA-21 (30 pts) 2.02* 0.02–11.26**
Table 2 Echocardiographic and invasive data
AVAi indexed aortic valve area, CI cardiac index, CO cardiac output, DT 
deceleration time, E/A ratio of early to late diastolic mitral filling velocity, E/e′ 
ratio of early diastolic velocity (PW) to tissue proto-diastolic velocity (TDI), EDDi 
indexed left ventricular end-diastolic diameter, EDPi invasive left ventricular 
end-diastolic pressure, EDVi, indexed left ventricular end-diastolic volume, 
EF, ejection fraction, ESDi, indexed left ventricular end-systolic diameter, ESVi, 
indexed left ventricular end-systolic volume, FS, fractional shortening, LAVi, 
indexed left atrial volume, LVMi, indexed left ventricular mass, MAPSE, mitral 
annular plane systolic excursion, RWT, relative wall thickness, s’L, systolic velocity 
(TDI) lateral, s’S, systolic velocity (TDI) septal, sPAP, systolic pulmonary arterial 
pressure, SVi, indexed stroke volume, TAPSE, tricuspid annular plane systolic 
excursion, ZVA, valvulo-arterial impedance
Mean SD
Valvular parameters
AVAi (cm2/m2) 0.45 0.09
Max gradient (mmHg) 80.2 16.76
Mean gradient (mmHg) 49.7 7.67
Peak-peak gradient (mmHg) 58.3 15.40
Velocity-ratio 0.18 0.04
Peak velocity (m/sec) 4.4 0.34
Non invasive haemodynamic data
SVi (mL/m2) 38.5 16.08
CI (L/min/m2) 2.5 0.72
CO (L/min) 4.8 1.45
ZVA (mmHg/ml/m
2) 5.9 1.26
Diastolic function parameters
EDPi (mmHg) (invasive) 16.81 6.81
LAVi (mL/m2) 48.2 12.65
E/A 0.8 0.33
E/e’ Average 18.4 8.39
DT (msec) 247.2 93.25
Conventional systolic function parameters (with TDI)
EF % 65.8 10.94
FS % 36.4 7.89
MAPSE (mm) 9.5 1.84
s’ l (cm/s) 6.4 1.50
s’s (cm/s) 5.6 1.49
Left and right ventricular echo parameters
EDDi (cm/m2) 2.52 0.25
EDVi (mL/m2) 50.28 12.95
ESDi (cm) 1.71 0.30
ESVi (mL/m2) 17.47 8.55
LVMi (g/m2) 149.5 20.7
RWT 0.51 0.07
sPAP (mmHg) 30.8 6.46
TAPSE (cm) 1.8 0.25
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Speckle tracking analysis
A significant impairment of global longitudinal deforma-
tion parameters (GLS) was observed (Table 3).
In particular, GLS showed a direct relationship with 
indexed LV stroke volume (SVi) (R2 =  0.20; p =  0.006) 
and a significant inverse relationship with BNP lev-
els (R2 =  0.47; p =  0.007). Modest inverse relationships 
between LVMi and AVAi (R2  =  0.16; p  =  0.01), ZVA 
(R2 =  0.12; p =  0.03) and GLS (R2 =  0.23; p =  0.002), 
were also observed. Septal sub-analysis showed higher 
impairment of deformation indices and a significant 
direct relationship of SSL with stroke volume (R2 = 0.22; 
p = 0.003).
Tissue analysis: myocardial fibrosis
A variable amount of MF (with absence of inflammatory 
cells) was a common finding in patients who performed 
biopsy.
To distinguish fibroblasts from inflammatory cells, 
immunohistochemistry was performed on myocar-
dial fibrosis for vimentin and CD45. Figure  1 clearly 
showed that myocardial fibrosis was composed not only 
by collagen fibres, highlighted by Masson’s Trichrome, 
but also by fibroblasts (vimentin positive); on the con-
trary only few inflammatory cells (CD45 positive) were 
present.
MF  % was associated (direct relationship) with EDPi 
(R2  =  0.31; p  =  0.03) and showed an inverse relation-
ship with SVi (R2  =  0.23; p  =  0.02). Moreover, MF 
showed a significant inverse relationship with deforma-
tion indices (GLS: R2 = 0.30 and p = 0.02; SSL: R2 = 0.36 
and p  =  0.01; SL-Sr: R2  =  0.39 and p  <  0.001; SL-SrE: 
R2 = 0.35 and p = 0.001) (in Fig. 2 two samples)
We did not find any relevant association between MF and 
other measures of LV systolic function (i.e. FE, MAPSE or 
TDI systolic velocities). Moreover, MF showed no associa-
tion with afterload parameters, including AVAi, ZVA and 
gradients. No relationships were found between MF and 
the major clinical and demographical parameters, such as 
age, duration of the disease, gender, history of diabetes mel-
litus, dyslipidemia, arterial hypertension and obesity.
Tissue and plasmatic miRNA‑21 analysis
While miRNA-21 was expressed both in myocytes and 
interstitial tissue, it resulted significantly more expressed 
in fibrous tissue (p  <  0.0001; Fig.  3). Tissue miRNA-21 
levels did not show an association with LVMi, body mass 
index (BMI), BSA or age. Conversely, interstitial miRNA-
21 was inversely related to septal and global longitudinal 
deformation (SSL: R2 = 0.32 and p = 0.01; GLS: R2 = 0.34 
Table 3 Speckle tracking and tissue data
GLS global longitudinal strain, MF myocardial fibrosis, miRNA micro-RNA, SL-Sr 
septal systolic strain rate, SL-SrE septal early-diastolic strain rate, SSL septal 
longitudinal strain
Mean SD
Speckle tracking
GLS % −14.02 3.88
Mean/median* SD/min–max**
Septal speckle tracking and 
tissue data (septum)
SL-Sr (1/sec) −0.58 0.17
SL-SrE (1/sec) 0.62 0.32
SSL (%) −9.63 2.97
MF % (n.23) 18.45* 5.13–98.0**
miRNA-21 myocardial expres-
sion/myocardial area (n.20)
0.416* 0.05–1.53**
miRNA-21 fibrotic/fibrotic area 
(n.20)
4.041* 0.57–22.27**
Fig. 1 Characterization of Fibrotic Areas (Immunohistochemistry). 
a Myocardial fibrosis is composed by collagen fibers with inter-
dispersed vimentin positive fibroblasts (arrows). b Only rare CD45 
positive inflammatory cells are encountered (arrow) (original magni-
fication, ×10)
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and p  =  0.008). Plasmatic miRNA-21 concentrations 
(n  =  30) demonstrated a significant direct relationship 
with whole MF (R2  =  0.31; p  =  0.001) and interstitial 
miRNA-21 compartment (R2 = 0.36; p = 0.001).
No relationships were found between plasmatic or tis-
sue miRNA-21 and the major clinical and demographical 
parameters.
Integrated speckle tracking and plasmatic miRNA‑21 
analysis
A significant and strong positive relationship between 
MF and plasmatic miRNA-21 was found, also after 
weighting for cardiac remodeling (assessed as LVMi: 
R2 = 0.50; p = 0.0005) and LV function parameters (SSL 
R2 = 0.35; p = 0.006; Fig. 4).
Fig. 2 Tissue samples. Samples from intra-operatory biopsies (a low and b high myocardial fibrosis at basal interventricular septum level), show-
ing myocardial fibrosis (Hematoxylin Eosin/Masson’s Trichrome). Region of interest (ROI) traced to derive longitudinal septal strain values (SSL %; c 
−11 %/d −8 %) are shown
Fig. 3 miRNA expression in tissue samples. Differential levels of expression of miRNA-21 in myocardial and interstitial tissue. The levels of expression 
(a) of miRNA-21 in the interstitial compart normalized for the area of fibrosis (21F) resulted higher (p < 0.0001) than in myocardial compart, normal-
ized for the myocardial area of the specimen (21M). In (b) a picture from a specimen
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Neither GLS nor SSL showed a significant diagnostic 
accuracy in MF evaluation using c-statistic approach. 
Conversely, patients with higher MF, showed a sig-
nificant higher mean level of expression of plasmatic 
miRNA-21. (Figure 5; with table showing differences in 
clinical profile).
At ROC analysis, a plasmatic miRNA-21 value >2.4552 
showed the best accuracy (Sensitivity 64.29 %; Specificity 
100 %; AUC 0.81; p = 0.001) for discriminating patients 
with significant MF (described as equal or more than 
10 % of the specimen).
No gender-based differences were found in the study.
Discussion
The main findings of the present paper are:
  • Patients with severe AVS show abnormalities of 
regional and global left ventricular myocardial strain, 
reflecting both pressure overload and geometric 
remodeling. These deformation abnormalities are 
related with the level of invasively measured MF 
(gold standard);
  • The expression of textural miRNA-21 determined 
with laser micro-dissection may document its patho-
physiological role in AVS. In particular, we focused 
on interdependence between textural miRNA-21 and 
fibrogenic stimulus induced by an abnormal left ven-
tricular pressure overload;
  • Circulating miRNA-21 (biomarker) levels are high 
in patients with severe AVS, reflecting the presence 
of significant myocardial fibrosis (defined as MF  % 
higher or lower than 10 %).
Deformation imaging and myocardial fibrosis in aortic 
stenosis
Conditions of LV pressure overload determine a deep 
remodeling of the extracellular matrix, with the secondary 
Fig. 4 Univariate regression (including 95 % confidence, prediction 
and line of equality) weighted for Left Ventricular Massi. Myocardial 
fibrosis in percentage (MF %) and plasmatic levels of micro-RNA-21 
(miRNA-21): R2 = 0.50; p = 0.0005
Fig. 5 Differential levels of expression of plasmatic miRNA-21 in patients with significant MF (MF % > 10 %). The plasmatic levels of miRNA-21 in 
patients with high MF (Over Ten = 1) resulted higher respective to the low fibrosis group (Median 5.5043 vs. 0.8854; p = 0.03). The table shows 
principal differences in clinical profiles. AVAi indexed aortic valve area, BNP brain natriuretic peptide, DT deceleration time, E/A ratio of early to late 
diastolic mitral filling velocity (PW), EF ejection fraction, eGFR estimated glomerular filtration rate, GLS global longitudinal strain, LVMi indexed left 
ventricular mass, MF Myocardial Fibrosis, RWT relative wall thickness
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deposition of MF. In the clinical setting, MF is known 
to be a deleterious consequence of AVS, contributing to 
systo-diastolic alterations and arrythmogenicity, affecting 
patients’ prognosis and quality of life after AVR. [27]
Meanwhile, we should not forget that in AVS, the para-
digm “Pressure overload—LV remodeling—Myocardial 
hypertrophy—interstitial and later replacement fibro-
sis” remains still not so definite: indeed, there is a wide 
variation, independent from the stage of the disease 
(especially if we consider only Valve Area). Thus, some 
patients with severe AVS have normal ventricular struc-
ture and no/mild fibrosis (10–30  %) while patients with 
only moderate AVS may have extensive hypertrophy and 
large amount of fibrosis [13, 25–27].
In our study population, despite a preserved EF, we 
found a significant amount of MF at endo-myocardial 
biopsy, confirming the insensitivity of EF in revealing 
subtle myocardial textural alterations. On the contrary, as 
previously reported, myocardial deformation parameters, 
assessed by 2D-STE, were altered (in a context of pre-
served EF) and inversely related to global afterload and 
remodeling parameters (LVMi) [12, 28, 29]. Similarly, we 
found a significant association between GLS and stroke 
volume, an important index for AVS re-classification 
and management [4]. Moreover, myocardial deformation 
indices showed a significant inverse association with tis-
sue MF, offering the potential appeal of a non-invasive, 
cost-effective (respective to MRI) tool for the detection of 
MF and for better AVS risk stratification.
In attempting to estimate MF, many non-invasive 
imaging modalities showed good correlation with tissue 
data [30, 31]. To our knowledge, while previous reports 
have shown a correlation between longitudinal echo 
parameters (MAPSE; strain TDI) [25, 26] or reflectivity 
indices (IBS) [32] and MF in AVS patients, the possible 
relationship between the presence and extent of MF and 
novel, more sensitive, echocardiographic parameters (i.e. 
2D-STE) has never been addressed before.
In our study, we did not find a significant association 
between MAPSE or TDI (systolic velocities) and textural 
parameters. These results are in line with recent studies 
conducted in patients with Hypertrophic Cardiomyopa-
thy that underwent septal miectomy. In fact, deformation 
parameters showed a strict correlation with myocardial 
fibrosis, while there was no association between MF and 
conventional echo parameters, including TDI [33, 34]. In 
addition, recent T1-mapping MRI techniques, found a sig-
nificant correlation between the signal and MF and between 
signal intensity and deformation indices (GLS). [35, 36]
microRNA and aortic valve stenosis
Recent evidences showed a key role for miRNAs, includ-
ing miRNA-21, in cardio-vascular pathophysiology. 
However, only few recent papers evaluated their involve-
ment in human heart, considering plasmatic and (sel-
dom) tissue pools [15]. Several previous findings have 
underlined the fibrogenic potential of miRNA-21 in 
hearts with superimposed pressure overload, mediating 
mRNA for fibrillar proteins. miRNA-21 already showed 
a pathophysiological role in AVS, with plasmatic levels 
resulting higher respective to controls and correlating 
with mean valvular gradient. [37]
To our knowledge, this is the first paper evaluating tis-
sue miRNA expression in biopsies of patients (in vivo) 
with AVS with LSMD, a more precise method respective 
to in situ hybridation (FISH).
In line with previous findings, tissue expression of 
miRNA was higher for interstitial compartment than 
myocardial tissue [37], with no relationship with myocar-
dial mass. The reason is probably because LVM reflects 
both myocardial and fibrous tissue compartment, while 
miRNA-21 is mainly limited to fibrous compartment, 
potentially (as we may argue from immunohistochemical 
findings) derived from fibroblasts. Interestingly, miRNA-
21 levels of expression in fibrous tissue, in line with their 
absolute over-expression at that level, showed a signifi-
cant inverse association with deformation indices. Most 
important, for plasmatic levels of miRNA-21, which 
already resulted elevated in previous cohorts of patients 
with AVS respective to controls [37–39], we found a 
direct association with MF and interstitial miRNA-21 
levels. This finding was stronger if weighted for LVMi (a 
gross indicator of “whole remodeling”) value. Thus, after 
validation in larger cohorts, plasmatic levels of miRNA-
21 could be used as a reliable biomarker of myocardial 
fibrosis [40].
Recently, miRNA plasmatic levels confirmed their 
strong fibrogenic implications in other similar contexts 
[41].
This may also open, in perspective, to myocardial fibro-
sis inhibition targeting, as very recently shown by Gupta 
et  al. in animal models of acute allograft cardiac trans-
plantation. [42]
Putting together the puzzle: dual‑step functional 
and textural analysis
We propose a complementary role of echocardiographic 
speckle tracking and plasmatic miRNA-21 analysis: 
the identification of the remodeling process (at macro-
scopic and tissue level) combined with a refined func-
tional approach. In particular, the evaluation of plasmatic 
miRNA together with GLS (by summing functional, 
structural and textural parameters) could help in better 
stratifying those patients that currently fall in a diagnos-
tic “gray zone” of AVS severity. Then, we can speculate a 
potential clinical implication in terms of clinical practice/
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safety (i.e. myocardial biopsy) and cost reduction (e.g. if 
we consider during the follow up other expensive imag-
ing procedures, such as magnetic resonance imaging). 
Present results underscore the tight relationship between 
valve and myocardium (in our opinion the “main actor” 
of this complex pathophysiological process), suggesting 
that only a combined evaluation of both variables may 
allow a complete evaluation of patients with AVS [7].
Limitations
The present work was designed as a pilot study. The main 
limitation of the study is its small sample size and, at pre-
sent, the absence of a follow-up. Analysis of plasmatic 
miRNA-21 is promising, but must be validated in larger 
studies, as its prognostic role and remodeling implica-
tions. To define a significant amount of MF evaluated 
with myocardial biopsy, we arbitrarily decided the cut-off 
of 10 %, according to the literature [13, 24].
So far, above all due to the limited cases collected, we 
didn’t have the objective to derive cut-off for plasmatic/
tissue values of miRNA-21.
Finally, this study was not designed to identify risk-
factors associated with MF in patients with AVS. There-
fore, it is possible that the small number of patients fails 
in showing significant differences between subjects with 
similar age and cardio-vascular risk profiles (diabetes, 
hypertension etc.). Anyway, consistent with previous 
and larger observations [25–27], the degree of hypertro-
phy/MF is not strictly associated with cardio-vascular 
risk profile. Genetic factors and gender are likely to play 
an important role in modulating myocardial response. 
This may explain the large inter-individual variability in 
remodeling and fibrosis observed in the setting of AVS.
Conclusions
In patients with severe AVS, myocardial fibrosis was 
associated with significant alterations of both plasmatic 
and textural miRNA-21 (biomarker) levels, as well as 
with impairment of regional and global longitudinal 
strain (functional marker). This combined bio-humoral 
and functional evaluation could allow a better defini-
tion of the remodeling process that takes place in AVS, 
possibly further improving risk stratification of patients. 
Prospective studies in larger populations of patients with 
AVS, are needed to better analyze the effective prog-
nostic value of this imaging and bio-humoral integrated 
approach, in order to shift the clinical focus also on myo-
cardium, beside valvular apparatus.
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